These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 25912693

  • 1. SYMPLICITY HTN-Japan - First Randomized Controlled Trial of Catheter-Based Renal Denervation in Asian Patients - .
    Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, Haskin R, Negoita M, Shimada K, SYMPLICITY HTN-Japan Investigators.
    Circ J; 2015; 79(6):1222-9. PubMed ID: 25912693
    [Abstract] [Full Text] [Related]

  • 2. Sufficient and Persistent Blood Pressure Reduction in the Final Long-Term Results From SYMPLICITY HTN-Japan　- Safety and Efficacy of Renal Denervation at 3 Years.
    Kario K, Yamamoto E, Tomita H, Okura T, Saito S, Ueno T, Yasuhara D, Shimada K, SYMPLICITY HTN-Japan Investigators.
    Circ J; 2019 Feb 25; 83(3):622-629. PubMed ID: 30760655
    [Abstract] [Full Text] [Related]

  • 3. Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial.
    Böhm M, Mahfoud F, Townsend RR, Kandzari DE, Pocock S, Ukena C, Weber MA, Hoshide S, Patel M, Tyson CC, Weil J, Agdirlioglu T, Fahy M, Kario K.
    Eur Heart J; 2019 Mar 01; 40(9):743-751. PubMed ID: 30608521
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL, SYMPLICITY HTN-3 Steering Committee Investigators.
    Lancet; 2022 Oct 22; 400(10361):1405-1416. PubMed ID: 36130612
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ultrasound-based renal sympathetic denervation for the treatment of therapy-resistant hypertension: a single-center experience.
    Fengler K, Höllriegel R, Okon T, Stiermaier T, Rommel KP, Blazek S, Besler C, von Roeder M, Petzold M, Schuler G, Lurz P.
    J Hypertens; 2017 Jun 22; 35(6):1310-1317. PubMed ID: 28441700
    [Abstract] [Full Text] [Related]

  • 9. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp ASP, Watkinson AF, Schmieder RE, Schmid A, Choi JW, East C, Walton A, Hopper I, Cohen DL, Wilensky R, Lee DP, Ma A, Devireddy CM, Lea JP, Lurz PC, Fengler K, Davies J, Chapman N, Cohen SA, DeBruin V, Fahy M, Jones DE, Rothman M, Böhm M, SPYRAL HTN-OFF MED trial investigators*.
    Lancet; 2017 Nov 11; 390(10108):2160-2170. PubMed ID: 28859944
    [Abstract] [Full Text] [Related]

  • 10. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
    Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators.
    J Am Coll Cardiol; 2014 Sep 16; 64(11):1071-8. PubMed ID: 24858423
    [Abstract] [Full Text] [Related]

  • 11. Renal denervation in moderate treatment-resistant hypertension.
    Ott C, Mahfoud F, Schmid A, Ditting T, Sobotka PA, Veelken R, Spies A, Ukena C, Laufs U, Uder M, Böhm M, Schmieder RE.
    J Am Coll Cardiol; 2013 Nov 12; 62(20):1880-6. PubMed ID: 23850901
    [Abstract] [Full Text] [Related]

  • 12. Long-term reduction in morning and nighttime blood pressure after renal denervation: 36-month results from SPYRAL HTN-ON MED trial.
    Kario K, Mahfoud F, Kandzari DE, Townsend RR, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Brar S, Hettrick DA, Fahy M, Böhm M.
    Hypertens Res; 2023 Jan 12; 46(1):280-288. PubMed ID: 36241705
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry.
    Mahfoud F, Bakris G, Bhatt DL, Esler M, Ewen S, Fahy M, Kandzari D, Kario K, Mancia G, Weber M, Böhm M.
    Eur Heart J; 2017 Jan 07; 38(2):93-100. PubMed ID: 28158510
    [Abstract] [Full Text] [Related]

  • 15. Renal Denervation for Treating Hypertension: Current Scientific and Clinical Evidence.
    Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Townsend RR, Kario K, Böhm M, Sharp ASP, Davies JE, Osborn JW, Fink GD, Euler DE, Cohen DL, Schlaich MP, Esler MD.
    JACC Cardiovasc Interv; 2019 Jun 24; 12(12):1095-1105. PubMed ID: 31221299
    [Abstract] [Full Text] [Related]

  • 16. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.
    Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP.
    Eur Heart J; 2014 Jul 24; 35(26):1752-9. PubMed ID: 24898552
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of sympathetic mapping and ablation of renal nerves for the treatment of hypertension (SMART): 6-month follow-up of a randomised, controlled trial.
    Wang J, Yin Y, Lu C, Lu Z, Hu J, Wang Y, Ge J, Jiang H, Yao C, Yan X, Ma W, Qi X, Dang Y, Chen S, Zhu J, Wang D, Ding C, Wang W, Liu J, Wang Y, Li H, Pan Z, Cui K, Li C, Liang X, Chen W, Sobotka PA, Zhang J, Esler M, Sun N, Chen M, Huo Y.
    EClinicalMedicine; 2024 Jun 24; 72():102626. PubMed ID: 38756107
    [Abstract] [Full Text] [Related]

  • 18. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications.
    Kandzari DE, Townsend RR, Kario K, Mahfoud F, Weber MA, Schmieder RE, Pocock S, Tsioufis K, Konstantinidis D, Choi J, East C, Lauder L, Cohen DL, Kobayashi T, Schmid A, Lee DP, Ma A, Weil J, Agdirlioglu T, Schlaich MP, Shetty S, Devireddy CM, Lea J, Aoki J, Sharp ASP, Anderson R, Fahy M, DeBruin V, Brar S, Böhm M, SPYRAL HTN-ON MED Investigators.
    J Am Coll Cardiol; 2023 Nov 07; 82(19):1809-1823. PubMed ID: 37914510
    [Abstract] [Full Text] [Related]

  • 19. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension.
    Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjønnæss E, Hjørnholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Høieggen A.
    Hypertension; 2014 May 07; 63(5):991-9. PubMed ID: 24591332
    [Abstract] [Full Text] [Related]

  • 20. Renal artery sympathetic denervation: observations from the UK experience.
    Sharp AS, Davies JE, Lobo MD, Bent CL, Mark PB, Burchell AE, Thackray SD, Martin U, McKane WS, Gerber RT, Wilkinson JR, Antonios TF, Doulton TW, Patterson T, Clifford PC, Lindsay A, Houston GJ, Freedman J, Das N, Belli AM, Faris M, Cleveland TJ, Nightingale AK, Hameed A, Mahadevan K, Finegold JA, Mather AN, Levy T, D'Souza R, Riley P, Moss JG, Di Mario C, Redwood SR, Baumbach A, Caulfield MJ, Dasgupta I.
    Clin Res Cardiol; 2016 Jun 07; 105(6):544-52. PubMed ID: 26802018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.